ABL1 and acute lymphoblastic leukemia: The highest cytotoxic potential against T-ALL cell lines and patient lymphoblasts was displayed by NVP-BAG956, a dual PI3K/PDK1 inhibitor which has been shown to be effective against BCR-ABL- and mutant FLT3-expressing acute leukemia cells [18].